Novavax, Inc. (NVAX) Earnings History
Net Loss30 years of earnings data (1996–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Novavax, Inc. (NVAX) Earnings Overview
As of November 8, 2026, Novavax, Inc. (NVAX) reported trailing twelve-month net income of -$77M, reflecting +306.5% year-over-year growth. The company earned $-0.47 per diluted share over the past four quarters, with a net profit margin of 39.2%.
Looking at the long-term picture, NVAX's historical earnings data spans multiple years. The company achieved its highest annual net income of $440M in fiscal 2025, representing a new all-time high.
Novavax, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including MRNA (-$2.79B net income, -145.2% margin), BNTX (-$1.48B net income, -39.6% margin), PFE ($4.03B net income, 12.4% margin), NVAX has outperformed on profitability metrics. Compare NVAX vs MRNA →
NVAX Earnings vs Peers
Earnings metrics vs comparable public companies
NVAX Historical Earnings Data (1996–2025)
30 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $440M | +334.8% | $563M | $2.54 | 39.2% | 50.1% |
| 2024 | -$187M | +65.6% | -$249M | $-1.23 | -27.5% | -36.5% |
| 2023 | -$545M | +17.2% | -$567M | $-5.41 | -98.0% | -101.8% |
| 2022 | -$658M | +62.3% | -$645M | $-8.42 | -41.1% | -40.3% |
| 2021 | -$1.74B | -316.9% | -$1.69B | $-23.44 | -882.5% | -853.6% |
| 2020 | -$418M | -221.5% | -$417M | $-7.43 | -1868.2% | -1861.3% |
| 2019 | -$130M | +29.6% | -$121M | $-5.40 | -697.1% | -646.1% |
| 2018 | -$185M | -0.5% | -$174M | $-9.99 | -538.8% | -507.2% |
| 2017 | -$184M | +34.4% | -$172M | $-12.56 | -589.5% | -550.8% |
| 2016 | -$280M | -78.4% | -$269M | $-20.68 | -1823.5% | -1752.8% |
| 2015 | -$157M | -89.2% | -$157M | $-11.97 | -432.9% | -433.8% |
| 2014 | -$83M | -59.6% | -$84M | $-7.35 | -270.5% | -273.0% |
| 2013 | -$52M | -82.4% | -$52M | $-6.13 | -248.5% | -250.7% |
| 2012 | -$29M | -47.2% | -$30M | $-4.33 | -129.1% | -134.4% |
| 2011 | -$19M | +45.8% | -$22M | $-3.41 | -131.8% | -146.9% |
| 2010 | -$36M | +6.9% | -$38M | $-6.82 | -10410.5% | -11222.7% |
| 2009 | -$38M | -6.4% | -$37M | $-8.97 | -11807.4% | -11502.5% |
| 2008 | -$36M | -3.7% | -$34M | $-10.58 | -3388.1% | -3229.3% |
| 2007 | -$35M | -50.7% | -$30M | $-11.38 | -2297.8% | -2000.7% |
| 2006 | -$23M | -106.4% | -$25M | $-7.86 | -492.6% | -525.5% |
| 2005 | -$11M | +56.9% | -$9M | $-5.23 | -151.2% | -124.1% |
| 2004 | -$26M | -50.1% | -$24M | $-14.04 | -313.8% | -296.2% |
| 2003 | -$17M | +23.9% | -$16M | $-11.57 | -146.6% | -136.2% |
| 2002 | -$23M | -132.9% | -$22M | $-18.58 | -151.3% | -143.7% |
| 2001 | -$10M | +20.1% | -$9M | $-8.60 | -40.5% | -38.5% |
| 2000 | -$12M | -170.9% | -$13M | $-12.82 | -492.6% | -514.8% |
| 1999 | -$5M | +6.3% | -$5M | $-6.20 | -375.0% | -383.3% |
| 1998 | -$5M | -6.7% | -$5M | $-7.72 | -685.7% | -742.9% |
| 1997 | -$5M | +18.2% | -$5M | $-7.71 | -900.0% | -960.0% |
| 1996 | -$6M | - | -$6M | $-10.86 | -5500.0% | -5500.0% |
Download Data
Export NVAX earnings history in CSV or JSON format
Free sign-in required to download data
NVAX Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
30+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NVAX — Frequently Asked Questions
Quick answers to the most common questions about buying NVAX stock.
What is NVAX earnings per share (EPS)?
NVAX trailing twelve-month (TTM) diluted EPS is $-0.47, reflecting +306.5% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1996 to 2025 is available in the table on this page.
What is Novavax, Inc.'s net income?
Novavax, Inc. (NVAX) trailing twelve-month net income is $-77M as of 2025. Earnings grew +306.5% year-over-year.
Is NVAX profitable?
NVAX is not currently profitable on a TTM basis, reporting a net loss of $-77M. Net margin is +39.2%. Investors should monitor for a return to profitability.
What is NVAX's earnings growth rate?
NVAX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1996 to 2025.
What are NVAX's profit margins?
Novavax, Inc. net profit margin is +39.2%, operating margin is +50.1%, and gross margin is +93.7%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is N/A.
Is NVAX growing earnings?
Yes, NVAX earnings are accelerating — EPS growth of +306.5% exceeds the 5-year CAGR of N/A. TTM net income reached $-77M. Earnings momentum is strengthening.
What was NVAX's best earnings year?
Novavax, Inc.'s highest annual net income on record is $440M, achieved in fiscal year 2025. Earnings history on this page spans 1996 to 2025 and includes all annual and quarterly figures.
What were NVAX's earnings last quarter?
NVAX's most recent reported quarter was Q3 2026. Net income was $-31M with diluted EPS of $-0.19. For a full breakdown of all quarters, see the quarterly earnings table on this page.